

## CURRICULUM VITAE

**NAME:** Andrea Cipriani

**DATE OF BIRTH:** 20.10.1972 (Montebelluna, Italy)

**CURRENT POSITIONS:** Associate Professor, Department of Psychiatry, University of Oxford

Honorary Consultant Psychiatrist at the Oxford Health NHS Foundation Trust

Lecturer in Psychiatry, University of Verona

Honorary Senior Registrar, South-Verona Community Mental Health Service (2005-2013)

**GMC REGISTRATION:** 7275098

**QUALIFICATIONS:** 1997 MD, University of Padua  
2004 Specialist in Psychiatry, University of Verona  
2008 PhD in Psychiatric Sciences, University of Verona

### TEACHING

- Undergraduate lecture course to students in clinical psychology about “Randomised Controlled Trials”, Isis Education Centre, Warneford Hospital, University of Oxford (2014)
- Medical student lectures Course about comparative efficacy of pharmacological treatments in psychiatry, Department of Psychiatry, University of Oxford (2014)
- MRCPsych Course, Department of Psychiatry, University of Oxford (2011-2012)
- Undergraduate lecture course “Clinical Psychiatry” for medical students at the Medical School, University of Verona (2005-2010)
- Lecture course *Neuropsychopharmacology* for postgraduate students in Psychiatry at the Medical School, University of Verona (2005-2013)
- Undergraduate lecture course “Rehabilitation Psychiatry” for Physiotherapy students, University of Verona (2007-2013)
- Lecture Course on *Psychopharmacology*, Master in Advanced Psychiatric Nursing, Bolzano, Italy (2008-2009)
- Undergraduate lecture course “Mental Health” for Nursing students, University of Verona (2009-2011)
- Lecture course *Psychopharmacology* for postgraduate students in Neurology at the Medical School, University of Verona (2010-2011).
- Lecture Course on *Pharmacoepidemiology*, Master in Farmacovigilanza e Discipline Regolatorie del Farmaco, University of Verona (2011-2013).

### POST-DOCTORAL STAGES

- Research fellow, Centre of Evidence-Based Medicine, University of Oxford (2002-2011)
- South-Verona Community Psychiatric Service, University of Verona (2000-2004)
- The Oxford, UK 2003 Evidence-Based Medicine Programme. “Randomised Clinical Trials: A practical guide to randomised clinical trial design, analysis, interpretation & reporting”.
- The Oxford, UK 2004 Evidence-Based Medicine Programme. “Workshop on the Practice of Evidence-Based Mental Health”.

## MAIN RESEARCH INTERESTS

- Systematic reviews and meta-analysis
- Randomised controlled trials
- Epidemiological psychiatry

## MEMBERSHIP OF PROFESSIONAL BODIES AND SCIENTIFIC SOCIETIES

- Member of the *International Society for Bipolar Disorders* (ISBD) (2011-present)
- Member of the *MORE – McMaster Online Rating of Evidence*, McMaster University, Hamilton, Ontario, Canada (2004-2011).
- Member, Italian National Guidelines Group, National Health Institute (Sistema Nazionale per le Linee Guida, Istituto Superiore di Sanità), Rome (2007-present)
- Expert reviewer, Agency for Healthcare Research and Quality ([www.ahrq.gov](http://www.ahrq.gov)), AHRQ's Effective Health Care Program, Rockville, Maryland (2010-present)
- Expert reviewer, South African Medical Research Council ([www.mrc.ac.za](http://www.mrc.ac.za)), Cape Town, South Africa (2010-present).
- Member of the *National Institute for Health and Clinical Excellence (NICE) Guideline Development Group for Bipolar Disorder (Update)*, National Collaborating Centre for Mental Health, London (2012-present).
- Member of the Clinical Trials Advisory Group (CTAG2) on Clinical Trial Data Formats, European Medicines Agency (2012-present)

## EDITORIAL WORK:

- Editor of *Evidence Based Mental Health* (2013-present)
- Editor of the *Cochrane Depression, Anxiety, & Neurosis Group*, The Cochrane Collaboration (2005-present).
- Team co-ordinator for the review on drug treatments, *Clinical Evidence: Depressive disorders in adults* - BMJ Publishing Group, London (2007-present)
- Member of the Advisory Board of:
  - *Lancet Psychiatry* (2013-present)
  - *Epidemiologia e Psichiatria Sociale (EPS)* (2008-2014)
  - *Current Drug Therapy* (2005-2011)
- Editorials for *British Medical Journal*, *The Lancet*, *British Journal of Psychiatry*
- **Referee for:** *American Journal of Psychiatry*, *Archives of General Psychiatry*, *Bipolar Disorders*, *British Journal of Psychiatry*, *British Medical Journal*, *The International Journal of Neuropsychopharmacology*, *Journal of the American Medical Association*, *Journal of Clinical Psychiatry*, *Journal of Clinical Psychopharmacology*, *Journal of Psychopharmacology*, *The Lancet*, *New England Journal of Medicine*, *PLoS Medicine*, *PLoS One*, *Psychiatry Research*, *Psychological Medicine*, *Schizophrenia Bulletin*, *Schizophrenia Research*.

## TRIAL INVESTIGATOR AND MONITORING COMMITTEES:

- 2005-2009: Chief investigator (Italy), "Bipolar Affective disorder: Lithium/ANti- Convulsant Evaluation" (BALANCE Trial; ISRCTN 55261332), Stanley Medical Research Institute, Grant ID 99-RC-998, 06TGF-951
- 2006-2010: Principal Co-Investigator, Clozapine Haloperidol and Aripiprazole Trial (CHAT),, Clinicaltrials.gov Identifier: NCT00395915

- 2008-present: Principal Co-Investigator, LAST Study - Randomized evaluation of the effectiveness of lithium in subjects with treatment-resistant depression and suicide risk. An independent, pragmatic, multicentre, parallel-group, superiority trial. Agenzia Italiana del Farmaco (Italian Drug Agency) - Cod.: FARM77Z3BL.
- 2011-present: Member, Trial Steering Committee of MRC-funded trial, CEQUEL-FA (Comparative evaluation of quetiapine plus lamotrigine vs quetiapine monotherapy and folic acid; PI: Professor John Geddes)
- 2012- present: Chief Co-Investigator (Italy), Evaluation of Mirtazapine and Folic Acid for Schizophrenia: A Large Simple 2x2 Factorial Trial (OCTUMI-4 Trial; ISRCTN32434568), Stanley Medical Research Institute, Grant ID 09T-002

## RESEARCH GRANTS:

- Federal Ministry of Education and Research,  
Cochrane review of implementation of treatment guidelines for specialist mental health care.  
Grant number 01KG1109, Germany  
Role: Co-applicant  
Date awarded – April 2009  
Amount: EUR 20,000
- Federal Ministry of Education and Research  
Systematic Review of Meta-Analyses on the Efficacy of SSRI and SNRI in the Treatment of Major Depression.  
Grant number 01KG0722, Germany  
Role: Co-applicant  
Date awarded – October 2010  
Amount: EUR 15,000
- Agenzia Italiana del Farmaco (Italian Drug Agency)  
LAST Study - Randomized evaluation of the effectiveness of lithium in subjects with treatment-resistant depression and suicide risk. An independent, pragmatic, multicentre, parallel-group, superiority trial  
Grant number: FARM77Z3BL  
Role: Co-applicant  
Date awarded – June 2008  
Amount: EUR 478,000

## PUBLICATIONS

### Books

Barbui C, Cipriani A, Saxena S. (2009) Pharmacological treatment of mental disorders in primary health care. WHO Press, World Health Organization: Geneva.

### Chapters

Cipriani A., Barbui C., Baethge H., Wilder H., Geddes J. (2005). Antidepressive Monotherapie. In: M. Bauer, A. Berghofer, M. Adli. Akute und therapieresistente Depressionen. p. 185-194, HEIDELBERG: Springer-Verlag

Cipriani A, Barbui C. (2007). Disturbi Bipolari. In: Vella L.. Enciclopedia Medica Italiana. p. 436-444, UTET Scienze Mediche

Barbui C., Cipriani A., Tansella M. (2007). Beneficial and adverse effects of antidepressants on suicide mortality in individuals with major depression. In: R. Tatarelli; M. Pompili; P. Girardi. Suicide in Psychiatric Disorders. p. 19-36, Nova Science Publishers Inc, ISBN: 1600217389

Cipriani A, Geddes JR. (2010). Randomised Controlled Trials. In: Stolerman I. (Ed.). Encyclopedia of Psychopharmacology. Springer-Verlag: Heidelberg.

Cipriani A, Barbui C (2012). Understanding and using systematic literature reviews In: Thornicroft G, Szumukler G, Mueser K, Drake R (eds). Oxford Textbook of Community Mental Health: Oxford University Press, Oxford.

## Papers

1. **Cipriani A.** Did you add the same study twice in the meta-analysis? The British journal of psychiatry: the journal of mental science 2005;207(2):177doi: 10.1192/bjp.207.2.177
2. Geddes, JR, Rendell J, **Cipriani A**, Saunders KEA, Attenburrow MJ, Bilderbeck AC, Goodwin GM, Nobre AC, Harmer CJ, Harrison PJ. Rationale and design of OxLith: a randomised placebo controlled trial exploring the short-term physical and psychological effects of lithium on mood instability. Bipolar Disorders 17: 110-110 June 2015 WOS: 000355338100307
3. **Cipriani A**, Miklowitz DJ, McMahon H, Chaimani A, Stockton S, Salanti G, Geddes JR. Bipolar Disorders 17:56-57 June 2015 WOS:000355338100147
4. Hayasaka Y, Purgato M, Magni LR, Ogawa Y, Takeshima N, **Cipriani A**, Barbui C, Leucht S, Furukawa TA. [Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials.](#) Journal of affective disorders **180**:179-184 Jul 2015 doi: [10.1016/j.jad.2015.03.021](#)
5. Mavridis D, Giannatsi M, **Cipriani A**, Salanti G. [A primer on network meta-analysis with emphasis on mental health.](#) Evidence-based mental health **18**(2):40-46 May 2015 doi:10.1136/eb-2015-102088
6. Levine SZ, Furukawa T, Tanaka S, Goldberg Y, Samara M, Davis J, **Cipriani A**, Leucht S. [INITIAL SEVERITY AND EFFICACY OF ANTIPSYCHOTICS FOR SCHIZOPHRENIA: INDIVIDUAL LEVEL ANALYSES OF SIX PLACEBO-CONTROLLED STUDIES](#) SCHIZOPHRENIA BULLETIN. 41: S319-S319. Mar 2015 (Conference)
7. Geddes JR, Rendell J, **Cipriani A**, Saunders KEA, Attenburrow MJ, Bilderbeck AC, Goodwin GM, Nobre AC, Harmer CJ, Harrison PJ Rationale and design of OxLith: a randomised placebo controlled trial exploring the short-term physical and psychological effects of lithium on mood instability. Bipolar Disorders 17:11-110 Jun 2015
8. Helfer B, Prosser A, Samara MT, Geddes JR, **Cipriani A**, Davis JM, Mavridis D, Salanti G, Leucht S *BMC Med* 2015 April 14; 13(1):82 Recent meta-analyses neglect previous systematic reviews and meta-analyses about the same topic: a systematic examination PMID: 25889502
9. Leucht S, Samara M, Heres S, Patel MX, Furukawa T, **Cipriani A**, Geddes J, Davis JM. Schizophrenia Bulletin. 3 April 2015. Dose equivalents for second-generation antipsychotic drugs: The classical mean dose method. doi: 10.1093/schbul/sbv037

10. **Cipriani A**, Reid K, Young AH, Macritchie KAN, Geddes J. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder *Advances in Psychiatric Treatment* 21(1):2 01 January 2015 DOI: 10.1192/apt.21.1.2
11. Furukawa TA, Levine SZ, Tanaka S, Goldberg Y, Samara M, Davis JM, **Cipriani A**, Leucht S. [Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.](#) *JAMA psychiatry* 72(1):14-21 Jan 2015 (Journal article) doi:10.1001/jamapsychiatry.2014.2127
12. Miura T, Furukawa TA, **Cipriani A**, Motomura K, Mitsuyasu H, Tanaka S, Leucht S, Shimano-Katsuki S, Salanti G, Noma H, Stockton S, Geddes JR, Kanba S. *Lancet Psychiatry* 1(6): 418-419 Nov 2014. Bipolar treatment efficacy Reply WOS: 000345635400012 DOI: 10.1016/S2215-0366(14)00011-X
13. Miura T, Noma H, Furukawa, TA, Mitsuyasu H, Tanaka S, Stockton S, Salanti G, Motomura K, Shimano-Katuski S, Leucht S, **Cipriani A**, Geddes JR, Kanba S, *Lancet Psychiatry* 1(5): 351-359 October 104 Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis doi:10.1016/S2215-0366(14)70314-1
14. Geddes JR **Cipriani A**, Horne R Communicating the harmful effects of medicines Warnings may have unintended consequences *BMJ* 2014 doi:http://www.bmj.com/content/348/bmj.g4047
15. Efthimiou O, Mavridis D, Riley RD, **Cipriani A**, Salanti G. [Joint synthesis of multiple correlated outcomes in networks of interventions.](#) *Biostatistics* (Oxford, England) 16(1):84-97 Jan 2015 (Journal article) doi: 10.1093/biostatistics/kxu030
16. **Cipriani A**, Geddes JR Placebo for depression: We need to improve the quality of scientific information but also reject too simplistic approaches or ideological nihilism *BMC Medicine* 2014 doi:10.1186/1741-7015-12-105
17. Brian Hutton, Fatemeh Yazdi, Salmaan Kanji, Kiran Rabheru, Ferran Catala-Lopez, **Andrea Cipriani**, Dean Fergusson, Lise Bjerre, Justin Theilmann, Andrea Tricco Sharon Straus, David Mother. Drug safety and effectiveness network report: systematic review of the association between serotonin affinity of anti-depressant agents and the occurrence of fractures, falls and bone mineral density change in patients with depression. On behalf of the NETMAN team February 2014
18. **Cipriani A**, Rendell J, Geddes JR, Barbui C Clinical and regulatory implications of active run-in phases in long-term studies for bipolar disorder *Acta Psychiatrica Scandinavica* 129(5):328-342 May 2014 DOI: 10.1111/acps.12223
19. Mavridis D, White IR, Higgins JP, **Cipriani A**, Salanti G. [Allowing for uncertainty due to missing continuous outcome data in pairwise and network meta-analysis.](#) *Statistics in medicine* 34(5):721-741 Feb 2014 (Journal article) DOI: 10.1002/sim.6365
20. Efthimiou O, Mavridis D, Mavridis D, **Cipriani A**, **Cipriani A**, Leucht S, Bagos P, Salanti G. [An approach for modelling multiple correlated outcomes in a network of interventions using odds ratios](#) *Statistics in Medicine* 33(13):2275-2287 15 Jun 2014 (Journal article) DOI: 10.1002/sim.6117
21. Barbui C, Giralanda F, Ay E, **Cipriani A**, Becker T, Koesters M. [Implementation of treatment guidelines for specialist mental health care.](#) *Schizophrenia bulletin* 40(4):737-739 Jul 2014 (Journal article) doi: 10.1093/schbul/sbu065
22. Leucht S, **Cipriani A**, Geddes JR, Salanti G, Davis JM. Efficacy of antipsychotic drugs for schizophrenia – Author’s reply. )7 Dec 2013 *Lancet* 382 (9908): 1874-1875. DOI: 10.1016/S0140-6736(13)62617-3 WOS:000328222400021

23. **Cipriani A**, Furukawa TA. (2014) Advancing evidence-based practice to improve patient care. *EVID BASED MENT HEALTH*. Vol. 17, p. 1-2. doi: 10.1136/eb-2014-101722.
24. Barbui C, Girlanda F, Ay E, **Cipriani A**, Becker T, Koesters M. (2014) Implementation of treatment guidelines for specialist mental health care. *COCHRANE DATABASE SYST REV*. Vol. 1:CD009780. doi: 10.1002/14651858.CD009780.pub2.
25. Barbui C, Conti V, **Cipriani A**. (2014) Antipsychotic drug exposure and risk of venous thromboembolism: a systematic review and meta-analysis of observational studies. *DRUG SAF*. Vol. 37, p. 79-90. doi: 10.1007/s40264-013-0127-6.
26. Tinazzi M, Morgante F, Matinella A, Bovi T, Cannas A, Solla P, Marrosu F, Nicoletti A, Zappia M, Luca A, Di Stefano A, Morgante L, Pacchetti C, Minafra B, Sciarretta M, Dallochio C, Rossi S, Ulivelli M, Ceravolo R, Frosini D, **Cipriani A**, Barbui C. (2014) Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: A 2-year follow-up multicenter study. *SCHIZOPHR RES*. Vol. 152, p 344-9. doi: 10.1016/j.schres.2013.11.028.
27. Magni LR, Purgato M, Gastaldon C, Papola D, Furukawa TA, **Cipriani A**, Barbui C. (2013) Fluoxetine versus other types of pharmacotherapy for depression. *COCHRANE DATABASE SYST REV*. Vol. 7:CD004185.
28. Leucht S, **Cipriani A**, Geddes JR, Salanti G, Davis JM. (2013) Efficacy of antipsychotic drugs for schizophrenia - Authors' reply. *LANCET*. Vol. 382, p. 1874-5. doi: 10.1016/S0140-6736(13)62617-3.
29. **Cipriani A**, Barbui C, Rendell J, Geddes JR. (2013) Clinical and regulatory implications of active run-in phases in long-term studies for bipolar disorder. *ACTA PSYCHIATR SCAND*. 2013 Nov 30. doi: 10.1111/acps.12223.
30. Barbui C, Bertolazzi A, Hanife B, **Cipriani A**. (2013) Treatment choices in women with bipolar disorder seeking pregnancy: a clinical case illustration. *CASE REP PSYCHIATRY*. 2013:630732. doi: 10.1155/2013/630732.
31. **Cipriani A**. (2013) Time to abandon Evidence Based Medicine? *EVID BASED MENT HEALTH*. Vol. 16, p. 91-2. doi: 10.1136/eb-2013-101604. PubMed PMID: 24163329.
32. **Cipriani A**, Reid K, Young AH, Macritchie K, Geddes J. (2013) Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. *COCHRANE DATABASE SYST REV*. Vol. 10:CD003196. doi: 10.1002/14651858.CD003196.pub2.
33. Koesters M, Guaiana G, **Cipriani A**, Becker T, Barbui C. (2013) Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials. *BR J PSYCHIATRY*. Vol. 203, p. 179-87. doi: 10.1192/bjp.bp.112.120196.
34. **Cipriani A**, Girlanda F, Agrimi E, Barichello A, Beneduce R, Bighelli I, Bisoffi G, Bisogno A, Bortolaso P, Boso M, Calandra C, Cascone L, Corbascio C, Parise VF, Gardellin F, Gennaro D, Hanife B, Lintas C, Lorusso M, Luchetta C, Lucii C, Cernuto F, Tozzi F, Marsilio A, Maio F, Mattei C, Moretti D, Appino MG, Nosè M, Occhionero G, Papanti D, Pecile D, Purgato M, Prestia D, Restaino F, Sciarma T, Ruberto A, Strizzolo S, Tamborini S, Todarello O, Ziero S, Zotos S, Barbui C. (2013) Effectiveness of lithium in subjects with treatment-resistant depression and suicide risk: a protocol for a randomised, independent, pragmatic, multicentre, parallel-group, superiority clinical trial. *BMC PSYCHIATRY*. Vol. 13, p. 212. doi: 10.1186/1471-244X-13-212.

35. Barbuì C, Gastaldon C, **Cipriani A**. (2013) Benzodiazepines and risk of dementia: true association or reverse causation? *EPIDEMIOLOGICAL PSYCHIATRY AND SCIENCE*. Vol. 22, p. 307-8. doi: 10.1017/S2045796013000358.
36. **Cipriani A**, Hawton K, Stockton S, Geddes JR. (2013) Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. *BMJ*. Vol. 346, p. f3646. doi: 10.1136/bmj.f3646.
37. **Cipriani A**, Accordini S, Nosè M, Purgato M, Girlanda F, Tansella M, Barbuì C. (2013) Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: a 12-month, randomized, naturalistic trial. *JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY*. Vol. 33, p. 533-7. doi: 10.1097/JCP.0b013e318296884f.
38. **Cipriani A**, Higgins JPT, Geddes JR, Salanti G. (2013). Conceptual and Technical Challenges in Network Meta-analysis. *ANNALS OF INTERNAL MEDICINE*. Vol. 159, p. 130-7. doi: 10.7326/0003-4819-159-2-201307160-00008.
39. **Cipriani A**, Accordini S, Nosè M, Purgato M, Girlanda F, Tansella M, Barbuì C. (2013). Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: a 12-month randomized, naturalistic trial. *JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY* (in press).
40. Leucht S, **Cipriani A**, Spinesi L, Mavridis D, Örey D, Richter F, Samara M, Barbuì C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM. (2013). Multiple treatments meta-analysis on the efficacy, effectiveness and tolerability of 15 antipsychotic drugs in schizophrenia. *LANCET*, vol. 382, p. 951-62. doi: 10.1016/S0140-6736(13)60733-3.
41. **Cipriani A**, Barbuì C. (2013). What is a factorial trial? *EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES*, vol. 22, p. 213-5. PMID: 23676770
42. Spinesi LM, Leucht S, **Cipriani A**, Higgins JP, Salanti G. (2013) The impact of trial characteristics on premature discontinuation of antipsychotics in schizophrenia. *EUROPEAN NEUROPSYCHOPHARMACOLOGY*, vol. 23, p. 1010-6. PMID: 23639793
43. **Cipriani A**, Barbuì C. (2013). Review: Short-term benefit of escitalopram versus citalopram for depression uncertain, but big difference in French health insurance costs. *EVIDENCE-BASED MENTAL HEALTH*, vol. 16, p. 51. doi: 10.1136/eb-2012-101196. PMID: 23525036
44. Barbuì C, Conti V, Purgato M, **Cipriani A**, Fortino I, Rivolta AL, Lora A. (2013). Use of antipsychotic drugs and mood stabilizers in women of childbearing age with schizophrenia and bipolar disorder: epidemiological survey. *EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES*, vol. 1, p. 1-7
45. Spinesi LM, Higgins JP, **Cipriani A**, Leucht S, Salanti G. Evaluating the impact of imputations for missing participant outcome data in a network meta-analysis. *CLINICAL TRIALS*, vol. 10, p. 378-88. doi: 10.1177/1740774512470317. PMID: 23321265
46. Barbuì C, **Cipriani A** (2012). Agomelatine and the brave old world of narrative-based medicine. *EVIDENCE-BASED MENTAL HEALTH*, vol. 15, p. 2-3, ISSN: 1362-0347
47. Barbuì C, **Cipriani A** (2012). Novel melatonin-based treatments for major depression. *LANCET*, vol. 379, p. 217-218, ISSN: 0140-6736
48. Purgato M, **Cipriani A**, Barbuì C (2012). Randomized trials published in Chinese or Western journals: comparative empirical analysis. *JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY*, p. 354-361, ISSN: 0271-0749

49. Mavridis D, **Cipriani A**, Sutton A, Salanti G (2012). A fully Bayesian application of the Copas selection model for publication bias extended to network meta-analysis. *STATISTICS IN MEDICINE*, p. 1-16,ISSN: 0277-6715
50. Conti V, Lora A, **Cipriani A**, Fortino I, Merlino L, Barbui C (2012). Persistence with pharmacological treatment in the specialist mental healthcare of patients with severe mental disorders. *EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY*, vol. 68, p. 1647-1655, ISSN: 0031-6970
51. Tinazzi M., **Cipriani A.**, Matinella A., Cannas A., Solla P., Nicoletti A., Zappia M., Morgante L., Morgante F., Pacchetti C., Sciarretta M., Dallochio C., Rossi S., Malentacchi M., Ceravolo R., Frosini D., Sestini S., Bovi T., Barbui C. (2012). [(123)I]FP-CIT single photon emission computed tomography findings in drug-induced Parkinsonism. *SCHIZOPHRENIA RESEARCH*, vol. 139, p. 40-45, ISSN: 0920-9964, doi:10.1016/j.schres.2012.06.003
52. **Cipriani A**, Koesters M, Furukawa TA, Nosè M, Purgato M, Omori IM, Trespidi C, Barbui C (2012). Duloxetine versus other anti-depressive agents for depression. *COCHRANE LIBRARY*, p. 1-197, ISSN: 1465-1858, doi: 10.1002/14651858.CD006533.pub2
53. **Cipriani A**, Barbui C, Rizzo C, Salanti G. (2012). What is a multiple treatments meta-analysis?. *EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES*, vol. 21, p. 151-153, ISSN: 2045-7960
54. **Cipriani A**, Purgato M, Furukawa TA, Trespidi C, Imperadore G, Signoretti A, Churchill R, Watanabe N, Barbui C (2012). Citalopram versus other anti-depressive agents for depression.. *COCHRANE LIBRARY*, p. 1-352, ISSN: 1465-1858
55. Barbui C, **Cipriani A**, Patel V, Ayuso-Mateos JL, van Ommeren M (2011). Efficacy of antidepressants and benzodiazepines in minor depression: systematic review and meta-analysis. *BRITISH JOURNAL OF PSYCHIATRY*, vol. 198, p. 11-16, ISSN: 0007-1250, doi: 10.1192/bjp.bp.109.076448
56. Barbui C., Accordini S., Nosè M., Stroup S., Purgato M., Girlanda F., Esposito E., Veronese A., Tansella M., **Cipriani A.** (2011). Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial. *JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY*, vol. 31, p. 266-273, ISSN: 0271-0749, doi:10.1097/JCP.0b013e318219cba3
57. **Cipriani A.**, Barbui C., Salanti G., Rendell J., Brown R., Stockton S., Purgato M, Spinelli LM., Goodwin GM., Geddes JR. (2011). Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. *THE LANCET*, p. 1-10, ISSN: 0099-5355, doi: 10.1016/S0140-6736(11)60873-8
58. Barbui C., Baschiroto C, **Cipriani A.** (2011). EMA must improve the quality of its clinical trial reports. *BRITISH MEDICAL JOURNAL*, vol. May 25, p. 1-5, ISSN: 0959-8138, doi: 10.1136/bmj.d2291
59. **Cipriani A.**, Barbui C., Butler R., Hatcher S., Geddes JR. (2011). Depression in adults: drug and physical treatments.. *CLINICAL EVIDENCE*, vol. 2011, p. 1-40, ISSN: 1462-3846
60. Trespidi C., Barbui C., **Cipriani A.** (2011). Why it is important to include unpublished data in systematic reviews.. *EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES*, vol. 20, p. 133-135, ISSN: 2045-7960
61. Barbui C., **Cipriani A.** (2011). What are evidence-based treatment recommendations?. *EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES*, vol. 20, p. 29-31, ISSN: 2045-7960
62. Watanabe N, Omori IM, Nakagawa A, **Cipriani A**, Barbui C, Churchill R, Furukawa TA (2011). Mirtazapine versus other antidepressive agents for depression. *COCHRANE DATABASE OF SYSTEMATIC REVIEWS*, p. 1-173, ISSN: 1469-493X



63. Barbui C, **Cipriani A** (2011). Cluster randomised trials. EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES, p. 307-309, ISSN: 2045-7960
64. **Cipriani A**, Furukawa TA, Barbui C (2011). What is a Cochrane review?. EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES, vol. 20, p. 231-233, ISSN: 2045-7960
65. Barbui C., Baschiroto C., **Cipriani A**. (2010). Is aripiprazole as effective as risperidone in people with schizophrenia? Commentary. EVIDENCE-BASED MENTAL HEALTH, p. 13-14, ISSN: 1362-0347
66. Guaiana G., Barbui C., **Cipriani A**. (2010). Hydroxyzine for generalised anxiety disorder.. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, p. 1-75, ISSN: 1469-493X, doi: 10.1002/14651858.CD006815.pub2
67. **Cipriani A**, Ferla T.L., Furukawa T.A., Signoretti A., Nakagawa A., Churchill R., McGuire H., Barbui C. (2010). Sertraline versus other antidepressive agents for depression. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, p. 1-2, ISSN: 1469-493X
68. Omori I.M., Watanabe N., Nakagawa A., **Cipriani A**, Barbui C., McGuire H., Churchill R., Furukawa T.A. (2010). Fluvoxamine versus other anti-depressive agents for depression. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, vol. 3, p. 1-330, ISSN: 1469-493X, doi:10.1002/14651858.CD006114.pub2
69. Purgato M., Barbui C., **Cipriani A**. (2010). Assessing risk of bias in randomized controlled trials. EPIDEMIOLOGIA E PSICHIATRIA SOCIALE, vol. 19, p. 296-297, ISSN: 1121-189X, doi: 10.1705/539.6423
70. **Cipriani A**, Barbui C (2010). What is a clinical trial protocol?. EPIDEMIOLOGIA E PSICHIATRIA SOCIALE, vol. 19, p. 116-117, ISSN: 1121-189X, doi: 10.1705/496.5883
71. **Cipriani A**, Geddes J.R. (2010). What is a run-in phase?. EPIDEMIOLOGIA E PSICHIATRIA SOCIALE, vol. 19, p. 21-22, ISSN: 1121-189X
72. Watanabe N., Omori I.M., Nakagawa A., **Cipriani A**, Barbui C., McGuire H., Churchill R., Furukawa T.A. (2010). Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis. CNS DRUGS, vol. 24, p. 35-53, ISSN:1172-7047, doi: 10.2165/11319480-000000000-00000
73. **Cipriani A**, Rendell J, Geddes JR (2010). Olanzapine in the long-term treatment of bipolar disorder: A systematic review and meta-analysis. JOURNAL OF PSYCHOPHARMACOLOGY, vol. 24, p. 1729-1738, ISSN: 0269-8811, doi: 10.1177/0269881109106900
74. Geddes J.R., Goodwin G.M., Rendell J., Azorin J., **Cipriani A**, Ostacher M.J., Morriss R., Alder N., Juszczak E. (2010). Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. LANCET, vol. 375, p.385-395, ISSN: 0923-7577, doi: 10.1016/S0140-6736(09)61828-6
75. **Cipriani A**, Furukawa TA, Salanti G, Geddes JR, Higgins JPT, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C. (2009). Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. LANCET, vol. 373, p. 746-758, ISSN: 0140-6736, doi: 10.1016/S0140-6736(09)60046-5
76. Omori IM, Watanabe N, Nakagawa A, Akechi T, **Cipriani A**, Barbui C, McGuire H, Churchill R, Furukawa TA (2009). Efficacy, tolerability and side-effect profile of fluvoxamine

for major depression: meta-analysis. JOURNAL OF PSYCHOPHARMACOLOGY, vol. 23, p. 539-550, ISSN: 0269-8811, doi: 10.1177/0269881108089876

77. Barbui C, **Cipriani A**, Furukawa TA, Salanti G, Higgins JPT, Churchill R, Watanabe N, Nakagawa A, Omori IM, Geddes JR (2009). Making the best use of available evidence: the case of new generation antidepressants: a response to: are all antidepressants equal?. EVIDENCE-BASED MENTAL HEALTH, vol. 12, p. 101-104, ISSN: 1362-0347, doi: 10.1136/ebmh.12.4.101
78. Barbui C, **Cipriani A** (2009). Review: maintenance antidepressants reduce risk of relapse but effect is not as great in recurrent depression. EVIDENCE-BASED MENTAL HEALTH, vol. 12, p. 79, ISSN: 1362-0347, doi: 10.1136/ebmh.12.3.79
79. Barbui C, Ostuzzi G, **Cipriani A** (2009). SSRI plus supportive care more effective than supportive care alone for mild to moderate depression. EVIDENCE-BASED MENTAL HEALTH, vol. 12, p. 109, ISSN: 1362-0347, doi: 10.1136/ebmh.12.4.109
80. Nose M, S. Accordini, P. Artioli, F. Barale, C. Barbui, R. Beneduce, D. Berardi, G. Bertolazzi, B. Biancosino, A. Bisogno, R. Bivi, F. Bogetto, M. Boso, A. Bozzani, P. Bucolo, M. Casale, L. Cascone, L. Ciammella, A. Cicolini, G. Cipresso, **Cipriani A**, P. Colombo, B. D. Santo, M. D. Francesco, G. D. Lorenzo, W. D. Munzio, G. Ducci, A. Erlicher, E. Esposito, L. Ferrannini, F. Ferrato, A. Ferro, N. Fragomeno, V. F. Parise, M. Frova, F. Gardellin, N. Garzotto, A. Giambartolomei, G. Giupponi, L. Grassi, N. Grazian, L. Grecu, G. Guerrini, F. Laddomada, E. Lazzarin, C. Lintas, F. Malchiodi, L. Malvini, L. Marchiaro, A. Marsilio, M. C. Mauri, A. Mautone, M. Menchetti, G. Migliorini, M. Mollica, D. Moretti, S. Mule, S. Nicholau, F. Nose, G. Occhionero, A. M. Pacilli, S. Pecchioli, M. Percudani, E. Piantato, C. Piazza, F. Pontarollo, R. Pycha, R. Quartesan, L. Rillosi, F. Risso, R. Rizzo, P. Rocca, S. Roma, M. Rossattini, G. Rossi, G. Rossi, A. Sala, C. Santilli, G. Sarao, A. Sarnicola, F. Sartore, S. Scarone, T. Sciarma, A. Siracusano, S. Strizzolo, M. Tansella, G. Targa, A. Tasser, R. Tomasi, R. Travaglini, A. Veronese, S. Ziero (2009). Rationale and design of an independent randomized controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia.. TRIALS, vol. 10, p. 1-9, ISSN: 1745-6215, doi:10.1186/1745-6215-10-31
81. Geddes JR, Barbui C, **Cipriani A** (2009). Risk of suicidal behaviour in adults taking antidepressants. BRITISH MEDICAL JOURNAL, vol. 339, p. 411-414, ISSN: 1468-5833, doi: 10.1136/bmj.b3066
82. Barbui C, Signoretti A, Mulè S, Boso M, **Cipriani A** (2009). Does the addition of a second antipsychotic drug improve clozapine treatment?. SCHIZOPHRENIA BULLETIN, vol. 35, p. 458-468, ISSN: 0586-7614, doi: 10.1093/schbul/sbn030
83. Imperadore G., **Cipriani A.**, Signoretti A., Furukawa TA, Watanabe N., Churchill R., McGuire H., Barbui C., Purgato M. (2009). Citalopram versus other anti-depressive agents for depression . COCHRANE DATABASE OF SYSTEMATIC REVIEWS, p. 1-11, ISSN: 1469-493X, doi: 10.1002/14651858CD006534.
84. **Cipriani A**, Rendell JM, Geddes JR (2009). Olanzapine in long-term treatment for bipolar disorder. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, p. 1-2, ISSN: 1469-493X, doi:10.1002/14651858.CD004367.pub2
85. **Cipriani A.**, Boso M., Barbui C. (2009). Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, p. 1, ISSN: 1469-493X, doi: 10.1002/14651858.CD006324.pub2
86. **Cipriani A**, C. Santilli, T. A. Furukawa, A. Signoretti, A. Nakagawa, H. McGuire, R. Churchill, C. Barbui (2009). Escitalopram versus other antidepressive agents for depression. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, p. 1-10, ISSN: 1469-493X, doi: 10.1002/14651858.CD006532.pub2

87. Churchill R, D. Caldwell, H. McGuire, C. Barbui, **Cipriani A**, T. A. Furukawa, N. Watanabe, G. Lewis (2009). Reboxetine versus other antidepressive agents for depression. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, p. 1-11, ISSN: 1469-493X, doi: 10.1002/14651858.CD007852
88. Nakagawa A, N. Watanabe, I. M. Otori, C. Barbui, **Cipriani A**, H. McGuire, R. Churchill, T. A. Furukawa (2009). Milnacipran versus other antidepressive agents for depression. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, p. 1-10, ISSN: 1469-493X, doi: 10.1002/14651858.CD006529.pub2
89. Elamin B, D. N. Flynn, D. Bassler, M. Briel, P. Alonso-Coello, P. J. Karanicolas, G. H. Guyatt, G. Malaga, T. A. Furukawa, R. Kunz, H. Schünemann, M. H. Murad, C. Barbui, **Cipriani A**, V. M. Montori (2009). Choice of data extraction tools for systematic reviews depends on resources and review complexity. JOURNAL OF CLINICAL EPIDEMIOLOGY, vol. 62, p. 506-510, ISSN: 0895-4356, doi: 10.1016/j.jclinepi.2008.10.016
90. Barbui C., Andretta A.R., De Vitis G., Rossi E., D'Arienzo F., Mezzalana L., De Rosa M., **Cipriani A.**, Berti A., Nosè M., Tansella M., Bozzini L. (2009). Antidepressant drug prescription and risk of abnormal bleeding. A case-control study. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, vol. 29, p. 33-38, ISSN: 0271-0749, doi: 10.1097/JCP.0b013e3181929f7a
91. Barbui C, E. Esposito, **Cipriani A** (2009). Selective serotonin reuptake inhibitors and risk of suicide: A systematic review of observational studies. CMAJ, vol. 180, p. 291-297, ISSN: 0820-3946, doi:10.1503/cmaj.081514
92. **Cipriani A**, Geddes JR (2009). What is a randomised controlled trial?. EPIDEMIOLOGIA E PSICHIATRIA SOCIALE, vol. 18, p. 191-194, ISSN: 1121-189X
93. Esposito E, **Cipriani A**, C. Barbui (2009). Outcome reporting bias in clinical trials. EPIDEMIOLOGIA E PSICHIATRIA SOCIALE, vol. 18, p. 17-18, ISSN: 1121-189X
94. **Cipriani A.**, Girlanda F., Barbui C. (2009). Superiority, equivalence or non-inferiority?. EPIDEMIOLOGIA E PSICHIATRIA SOCIALE, vol. 18, p. 311-313, ISSN: 1121-189X
95. **Cipriani A**, M. Purgato, C. Barbui (2009). Why internal and external validity of experimental studies are relevant for clinical practice?. EPIDEMIOLOGIA E PSICHIATRIA SOCIALE, vol. 18, p. 101-103, ISSN: 1121-189X
96. Mazzucco S., **Cipriani A.**, Barbui C., Monaco S. (2008). Antipsychotic drugs and cerebrovascular events in elderly patients with dementia: a systematic review. MINI-REVIEWS IN MEDICINAL CHEMISTRY, vol. 8, p. 776-783, ISSN: 1389-5575
97. **Cipriani A.**, Geddes J.R. (2008). Antidepressants for Bipolar Disorder. PSYCHIATRIC TIMES, p. 36-39, ISSN: 0893-2905
98. **Cipriani A**, Dieterich M, Barbui C. (2008). Review: atypical antipsychotics are effective adjuncts for treatment resistant depression but increase discontinuation due to adverse effects. EVIDENCE-BASED MENTAL HEALTH, vol. 11, p. 14, ISSN: 1362-0347
99. **Cipriani A**, Barbui C. (2008). Adding aripiprazole improves major depressive disorder following incomplete response to antidepressants alone. EVIDENCE-BASED MENTAL HEALTH, vol. 11, p. 15, ISSN: 1362-0347
100. Barbui C, **Cipriani A** (2008). Cognitive improvements with antipsychotics: real or practice effect?. EVIDENCE-BASED MENTAL HEALTH, vol. 11, p. 42, ISSN: 1362-0347
101. Barbui C, **Cipriani A**, Geddes JR. (2008). Antidepressants and suicide symptoms: compelling new insights from the FDA's analysis of individual patient level data. EVIDENCE-BASED MENTAL HEALTH, vol. 11, p. 34-35, ISSN: 1362-0347

102. Veronese A., Hunot V., **Cipriani A.**, Churchill R., Barbui C. (2008). Psychological therapies versus pharmacotherapy for obsessive compulsive disorder (Protocol). COCHRANE DATABASE OF SYSTEMATIC REVIEWS, vol. Issue 3, p. 1, ISSN: 1469-493X
103. Barbui C, Furukawa TA, **Cipriani A.** (2008). Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials. CMAJ, vol. 178, p. 296-305, ISSN: 0820-3946
104. Nakagawa A, Watanabe N, Omori IM, Barbui C, **Cipriani A.**, McGuire H, Churchill R, Furukawa TA, Multiple Meta-Analyses of New-Generation Antidepressants (MANGA) Study Group. (2008). Efficacy and tolerability of milnacipran in the treatment of major depression in comparison with other antidepressants : a systematic review and meta-analysis. CNS DRUGS, vol. 22, p. 587-602, ISSN: 1172-7047
105. **Cipriani A.**, Barbui C. (2008). What is an intention to treat analysis? . EPIDEMIOLOGIA E PSICHIATRIA SOCIALE, vol. 17, p. 26-27, ISSN: 1121-189X
106. Veronese A., Vivenza V., Nosè M., **Cipriani A.**, Tansella M., Barbui C. (2008). Understanding antipsychotic non-classical prescriptions: a quantitative and qualitative approach. EPIDEMIOLOGIA E PSICHIATRIA SOCIALE, vol. 17, p. 236-241, ISSN: 1121-189X
107. **Cipriani A.**, Nosè M, Barbui C (2008). Allocation concealment and blinding in clinical trials. EPIDEMIOLOGIA E PSICHIATRIA SOCIALE, vol. 17, p. 115-116, ISSN: 1121-189X
108. **Cipriani A.**, Furukawa T.A., Geddes J., Malvini L., Signoretti A., McGuire H., Churchill R., Nakagawa A., Barbui C. (2008). Does randomised evidence support sertraline as first-line antidepressant for adults with acute major depression? A systematic review and meta-analysis. JOURNAL OF CLINICAL PSYCHIATRY, vol. 69, p. 1732-1742, ISSN: 0160-6689
109. Watanabe N, Omori IM, Nakagawa A, **Cipriani A.**, Barbui C, McGuire H, Churchill R, Furukawa TA, Multiple Meta-Analyses of New Generation Antidepressants (MANGA) Study Group. (2008). Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and meta-analysis. JOURNAL OF CLINICAL PSYCHIATRY, vol. 69, p.1404-1415, ISSN: 0160-6689
110. Mulè S., **Cipriani A.**, Barbui C (2008). Aripiprazole in addition to clozapine in partially responsive patients with schizophrenia: a critical review of case series. CLINICAL SCHIZOPHRENIA & RELATED PSYCHOSES, vol. 1, p. 341-347, ISSN: 1935-1232
111. **Cipriani A.**, Malvini L., Furukawa T., Barbui C. (2007). Relationship between quality of reports of antidepressant randomized controlled trials and treatment estimates: systematic review, meta-analysis, and meta-regression analysis. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, vol. 27, p. 352-356, ISSN: 0271-0749
112. **Cipriani A.**, Geddes J.R., Barbui C. (2007). Venlafaxine for major depression: more evidence that risks outweigh benefits for most patients?. BMJ. BRITISH MEDICAL JOURNAL, vol. 334, p. 215-216, ISSN: 0959-8138
113. **Cipriani A.**, Nakonezny P. (2007). Adherence therapy does not improve quality of life in people with schizophrenia [Comment]. EVIDENCE-BASED MENTAL HEALTH, vol. 10, p. 75, ISSN: 1362-0347
114. **Cipriani A.**, Signoretti A., Barbui C. (2007). Commentary: Antipsychotic plus mood stabilizer co-therapy is more effective than mood stabiliser mono-therapy at reducing acute bipolar mania. EVIDENCE-BASED MENTAL HEALTH, vol. 10, ISSN: 1362-0347

115. Barbui C., Mulè S., **Cipriani A.** (2007). Commentary: Haloperidol, risperidone and olanzapine are similarly effective for first-episode non-affective psychosis but have differing side effects. EVIDENCE-BASED MENTAL HEALTH, vol. 10, ISSN: 1362-0347
116. **Cipriani A.**, Barbui C. (2007). Pharmacological treatment for unipolar psychotic depression. EVIDENCE-BASED MENTAL HEALTH, ISSN: 1362-0347
117. **Cipriani A.**, Barbui C. (2007). Review: antidepressant plus antipsychotic increases clinical response rates in psychotic depression (Commentary). EVIDENCE-BASED MENTAL HEALTH, ISSN: 1362-0347
118. Barbui C., **Cipriani A.** (2007). Evidence based psychopharmacology: a public health agenda for the future. EVIDENCE-BASED MENTAL HEALTH, p. 4-6, ISSN: 1362-0347
119. Barbui C., **Cipriani A.**, Lintas C., Bertelè V., Garattini S. (2007). CNS drugs approved by the centralised European procedure: true innovation or dangerous stagnation? PSYCHOPHARMACOLOGY, p. 265-268, ISSN: 0033-3158
120. Veronese A., Garatti M., **Cipriani A.**, Barbui C. (2007). Benzodiazepine use in the real world of psychiatric practice: low-dose, long-term drug taking and low rates of treatment discontinuation. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, vol. 62, p. 867-873, ISSN: 0031-6970
121. Geddes J.R., Furukawa T., **Cipriani A.**, Barbui C. (2007). Depressive Disorder needs an evidence base commensurate with its public health importance. CANADIAN JOURNAL OF PSYCHIATRY, vol. 52, p. 543-544, ISSN: 0706-7437
122. Furukawa T., **Cipriani A.**, Barbui C., Geddes J.R. (2007). Long-term treatment of depression with antidepressants: A systematic narrative review. CANADIAN JOURNAL OF PSYCHIATRY, vol. 52, p. 545-552, ISSN: 0706-7437
123. **Cipriani A.**, Geddes J.R., Furukawa T., Barbui C. (2007). Metareview on short-term effectiveness and safety of antidepressants for depression: An evidence-based approach to inform clinical practice. CANADIAN JOURNAL OF PSYCHIATRY, vol. 52, p. 553-562, ISSN: 0706-7437
124. **Cipriani A.**, Barbui C. (2007). What is an individual patient data meta-analysis?. EPIDEMIOLOGIA E PSICHIATRIA SOCIALE, vol. 16, p. 203-204, ISSN: 1121-189X
125. **Cipriani A.**, Nosè M., Barbui C. (2007). What is a risk ratio?. EPIDEMIOLOGIA E PSICHIATRIA SOCIALE, vol. 16, p. 20-21, ISSN: 1121-189X
126. Barbui C., Veronese A., **Cipriani A.** (2007). Explanatory and pragmatic trials. EPIDEMIOLOGIA E PSICHIATRIA SOCIALE, p. 124-125, ISSN: 1121-189X
127. Barbui C., **Cipriani A.** (2007). Publication bias in systematic reviews. ARCHIVES OF GENERAL PSYCHIATRY, ISSN: 0003-990X
128. **Cipriani A.**, Barbui C. (2007). Is the onset of action of antidepressants truly delayed? [Letter]. CLINICAL EVIDENCE, p. 1-4, ISSN: 1462-3846
129. Barbui C., Butler R., **Cipriani A.**, Geddes J.R., Hatcher S. (2007). Depression in adults (drug and other physical treatments). CLINICAL EVIDENCE, ISSN: 1462-3846
130. Nosè M, **Cipriani A.**, Biancosino B, Grassi L, Barbui C (2006). Efficacy of pharmacotherapy against core traits of borderline personality disorder. Meta-analysis of randomized controlled trials. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, vol. 21, p. 345-353, ISSN: 0268-1315

131. **Cipriani A.**, Barbui C. (2006). What is a systematic review?. EPIDEMIOLOGIA E PSICHIATRIA SOCIALE, vol. 15, p. 174-175, ISSN: 1121-189X
132. Furukawa T.A, Barbui C., **Cipriani A**, Brambilla P. Watanabe N., Furukawa T.A. (2006). Imputing missing standard deviations in meta-analyses can provide accurate results. JOURNAL OF CLINICAL EPIDEMIOLOGY, vol. 59, p. 7-10, ISSN: 0895-4356
133. Barbui C., **Cipriani A**, Malvini L, Tansella M. (2006). Validity of the impact factor of journals as a measure of randomised controlled trial quality. JOURNAL OF CLINICAL PSYCHIATRY, vol. 67, p. 37-40, ISSN: 0160-6689
134. **Cipriani A.**, Barbui C., Brambilla P, Furukawa T.A, Hotopf M., Geddes J. (2006). Are all antidepressants really the same? The case of fluoxetine: a systematic review. JOURNAL OF CLINICAL PSYCHIATRY, vol. 67, p. 850-864, ISSN: 0160-6689
135. **Cipriani A.**, Barbui C., Brambilla P, Furukawa T.A, Hotopf M., Geddes J. (2006). Are all antidepressants really the same? The case of fluoxetine: a systematic review. JOURNAL OF CLINICAL PSYCHIATRY, vol. 67, p. 850-864, ISSN: 0160-6689
136. Butler R., Carney S., **Cipriani A.**, Geddes J., Hatcher S., Price J., VonKorff M. (2006). Depressive disorders. AMERICAN FAMILY PHYSICIAN, vol. 73, ISSN: 0002-838X
137. Mazzucco S, **Cipriani A**, Lintas C, Barbui C. (2006). Effect of antipsychotic drugs on cerebrovascular morbidity and mortality: a systematic review. CURRENT DRUG THERAPY, vol. 241-248, ISSN: 1574-8855
138. Barbui C., **Cipriani A.**, Malvini L., Nosè M., Accordini S., Pontarollo F., Veronese A., Tansella M. (2006). Trasformare la pratica clinica in ricerca. Un invito a partecipare allo studio CHAT. RIVISTA DI PSICHIATRIA, vol. 41, p. 326-330, ISSN: 0035-6484
139. Malvini L., **Cipriani A.**, Furukawa T., McGuire H., Churchill R., Barbui C., for the MANGA Study (2006). Sertraline versus other antidepressive agents for depression. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, ISSN: 1469-493X
140. **Cipriani A.**, Smith K., Burgess S., Carney S., Goodwin G., Geddes J. (2006). Lithium versus antidepressants in the maintenance treatment of depressive disorder (Review). COCHRANE DATABASE OF SYSTEMATIC REVIEWS, ISSN: 1469-493X
141. **Cipriani A.**, Rendell J.M., Geddes J.R. (2006). Haloperidol alone or in combination for acute mania (Review). COCHRANE DATABASE OF SYSTEMATIC REVIEWS, ISSN: 1469-493X
142. Tansella M, Thornicroft G, Barbui C., **Cipriani A.**, Saraceno B. (2006). Seven criteria to improve effectiveness trials in psychiatry. PSYCHOLOGICAL MEDICINE, vol. 36, p. 711-720, ISSN: 0033-2917
143. Geddes J., Butler R., Hatcher S., **Cipriani A.**, Price J., Carney S., Von Korff M. (2006). Depression in adults. CLINICAL EVIDENCE, vol. 15, p. 1366-1406, ISSN: 1462-3846
144. Patten S, **Cipriani A**, Brambilla P, Nosè M, Barbui C (2005). International dose differences in fluoxetine clinical trials conducted in patients with depression. CANADIAN JOURNAL OF PSYCHIATRY, vol. 50, p. 31-38, ISSN: 0706-7437
145. **Cipriani A**, Barbui C, Geddes J (2005). Suicide, depression, and antidepressants. Patients and clinicians need to balance benefits and harms. BRITISH MEDICAL JOURNAL, vol. 330, p. 373-374, ISSN: 0959-535X
146. **Cipriani A.**, Hawton K., Wilder H., Geddes J. (2005). Lithium in the prevention of suicidal behaviour and all-cause mortality in patients with mood disorders: a systematic review of randomised trial. THE AMERICAN JOURNAL OF PSYCHIATRY, vol. 162, p. 1805-1819, ISSN: 0002-953X
147. Butler R., Carney S., **Cipriani A.**, Geddes J., Hatcher S., Price J., Von Korff M. (2005). Depressive disorders. CLINICAL EVIDENCE, vol. 14, p. 1-40, ISSN: 1462-3846

148. **Cipriani A.**, Brambilla P., Furukawa T.A., Geddes J., Gregis M., Hotopf M., Malvini L., Barbui C. (2005). Fluoxetine versus other types of pharmacotherapy for depression (Review). COCHRANE DATABASE OF SYSTEMATIC REVIEWS, vol. 4, ISSN: 1469-493X
149. **Cipriani A.**, Barbui C. (2005). Inglobare la ricerca nella pratica clinica quotidiana. PSICHIATRIA DI COMUNITA', vol. 4, p. 164-166., ISSN: 1724-0751
150. **Cipriani A.** (2005). Forensic database study suggests selective serotonin reuptake inhibitors do not increase the risk of suicide in people taking antidepressants. EVIDENCE-BASED MENTAL HEALTH, vol. 8, ISSN: 1362-0347
151. Furukawa T.A., **Cipriani A.**, Barbui C., Brambilla P., Watanabe N. (2005). Imputing response rates from means and standard deviations in meta-analyses. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, vol. 20, p. 49-52, ISSN: 0268-1315
152. Andretta M., Ciuna A., Corbari L., **Cipriani A.**, Barbui C. (2005). Impact of regulatory changes on first- and second-generation antipsychotic drug consumption and expenditure in Italy. SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY, vol. 40, p. 72-77, ISSN: 0933-7954
153. Brambilla P., **Cipriani A.**, Hotopf M., Barbui C. (2005). Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: a meta-analysis of clinical trial data. PHARMACOPSYCHIATRY, vol. 50, p. 31-38, ISSN: 0176-3679
154. Barbui C., **Cipriani A.**, Brambilla P., Hotopf M. (2004). Wish bias in antidepressant drug trials? JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, vol. 24, p. 126-130, ISSN: 0271-0749
155. Geddes J., **Cipriani A.** (2004). Selective serotonin reuptake inhibitors. BMJ. BRITISH MEDICAL JOURNAL, vol. 329, p. 809-810, ISSN: 0959-8138
156. **Cipriani A.**, Geddes J. (2004). Commentary on: Analysis and reporting of factorial trials: a systematic review (McAlister et al., JAMA). COCHRANE COLLABORATION METHODS GROUPS NEWSLETTER, vol. 8, p. 20-21, ISSN: 1503-3236
157. Geddes J.R., Butler R., Hatcher S., **Cipriani A.**, Barbui C., Price J., Carney S., Von Korff M. (2004). Depressive disorders. CLINICAL EVIDENCE, p. 1391-1436, ISSN: 1462-3846
158. **Cipriani A.**, Geddes J. (2003). Comparison of systematic and narrative reviews: the example of the atypical antipsychotics. EPIDEMIOLOGIA E PSICHIATRIA SOCIALE, vol. 12, p. 146-153, ISSN: 1121-189X
159. **Cipriani A.**, Geddes J. (2003). Commentary to: Review: selective serotonin reuptake inhibitors as effective as tricyclic antidepressants for major depression, and may have fewer adverse effects [by MacGillivray et al.]. EVIDENCE-BASED MENTAL HEALTH, ISSN: 1362-0347.